Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT03806153
Active, not recruiting Not applicable

Interest of Morphokinetic Parameters of Early Embryonic Development in the Birth Rates in Vitro Fertilization

NCT03806153 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Rouen
Phase
Not applicable
Started
2020-10-26
Last updated
2026-09-28

Condition(s) studied

Reproductive Disorder

Investigational drug(s) / intervention(s)

Morphokinetic

Morphokinetic: The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).

Study summary

In France, nearly 3% of children are conceived by the technique of Assisted Reproductive Medicine, of which nearly 70% by in vitro fertilization (IVF). The rates of clinical pregnancy by oocyte retrieval or embryo transfer have not changed much. The use of mono-embryo transfer reduces the risk of multiple pregnancies and associated obstetric complications. The choice of embryo to transfer or freeze is a key element in improving the chances of success of IVF. It is usually based on conventional morphological criteria (reference method) that are punctual, qualitative and subjective. However, embryo morphology at early stages has little predictive value for obtaining a late-stage embryo and its chances of implantation. The recent use of time-lapse technology during embryonic culture makes it possible to associate morphological criteria with continuous monitoring of the kinetics of embryonic development. The choice of the embryo to be transferred is then made according to morphokinetic criteria (conventional morphological criteria to which are added the data of the kinetics of embryonic development).

Two recent retrospective studies give contradictory results, the first shows higher birth rates in the group of embryos selected according to conventional morphological criteria, the second concludes that morphokinetic analysis is superior. Morphokinetic criteria would also be more objective and reproducible. However, the use of morphokinetic parameters remains controversial in the literature.

Eligibility

Sex
ALL
Min age
18 Years
Max age
59 Years
Healthy volunteers
No
Inclusion Criteria: 1. For the couple: * Couple whose two members are 18 years old and over, * Couple whose two members are affiliated to a social security scheme, * Couple whose two members read and understood the newsletter and signed the consent form for their participation in this research. 2. For the conditions of realization of the ICSI attempt: * Couple supported for a 1st or 2nd attempt at in vitro fertilization with sperm microinjection (ICSI) for male infertility, * In vitro fertilization attempt performed with micro-injection of fresh ejaculated spermatozoa. 3. For the man: * Couple whose man has an alteration of at least one of the sperm parameters according to the WHO (WHO, 2010) for the number, concentration, vitality, mobility or morphology according to the modified David classification (Auger and Eustache, 2000). Exclusion Criteria: 1. For the couple: * Couple whose wife is under 18 and over 42 and / or the male is under 18 and over 59 * Couple already included in the protocol "EMCIMO" for a previous attempt, * Couple of which one or both members is deprived by an administrative or judicial decision or subject to a legal measure of protection of the majors (safeguard of justice or tutelage or curatorship), * Couple where one or both members do not speak or understand French. 2. For the conditions of realization of the ICSI attempt: \- In vitro fertilization attempt with the micro-injection of testicular spermatozoa, epididymal, previously frozen or resulting from a retrograde ejaculation. 3. For the man: * Severe oligozoospermia (\<100,000 spermatozoa / ejaculate).

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
CHU CAEN Caen France
Chu Rouen Rouen France

More University Hospital, Rouen trials in France

Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy Recruiting
Non-invasive Ventilation and High-speed Oxygen Therapy Effects on Heart Function - HiFlow-Heart Study Recruiting
Prediction of Postoperative Pulmonary Complications in Thoracic Surgery Starting soon
APA (Adapted Physical Activity) for Patients With Advanced Melanoma Recruiting
Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Juxtarenal Abdominal Aortic Aneurysm Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03806153 on ClinicalTrials.gov ↗ ← All trials in France